Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 23129

    +

    P2.01-006 - Effect of Maintenance Using Pemetrexed with and without Bevacizumad in Patients Advanced Lung Cancer in Non-Small Cells (ID 7941)

    09:00 - 09:00  |  Author(s): M. Magallanes Maciel
    • Abstract
    • Slides

    Background:
    Lung cancer is the first cause of death by cancer in Mexico, the chemotherapy based on platin is the regular treatment for the advanced stages of this disease; adding bevacizumab to the chemotherapy gave better results in the average response and the progression-free survival. A common strategy is the maintenance therapy, which is used to maintain the response to the initial therapy after the chemotherapy. The objective is to evaluate and to contrast the effect on the progression-free survival of the combined scheme of “Bevacizumab and Pemetrexed” versus the use of only “Pemetrexed” as a maintenance therapy in patients with advanced lung cancer in non-small cells.better results in progression-free survival.
    
    Method:
    Observational, analytic, transversal, retrospective studies. Patients with advanced lung adenocarcinoma negative EGFR and ALK who received maintenance therapy with pemetrexed/bevacizumab after have shown response at the first line of chemotherapy based on platin/pemetrexed.
    
    Result:
    Twenty-two patients were analyzed. Eleven of them received pemetrexed/carboplatin and bevacizumab at the first line followed by pemetrexed/bevacizumab. And, the other eleven received pemetrexed/carboplatin followed by a maintenance therapy with pemetrexed. All of them were in the clinic stage IV. 45% of the patients in both groups showed distance metastasis (meaning more frequent). The progression-free survival was the same in both groups of treatment with an average of sixteen months (HRE 0.76 (IC 95% 0.24-2.35), Log Rank P=0.62)Figure 1.
    
    
    
    Conclusion:
    Patients having lung adenocarcinoma without activating mutations using bevacizumab as maintenance therapy do not have better results in progression-free survival.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.